Bioavailability, Genetics and Immune Response

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

Genetics

Immune Response

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

Cloudbyz

MARCH 5, 2024

They are often used to mimic or enhance natural biological processes, such as immune responses. Immunogenicity : Small Molecules: Generally have a lower risk of inducing an immune response in the body. Enhancing bioavailability is often a key focus in the development of small molecule drugs.

Development

Development Drugs Manufacturing Immune Response

Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence?

Delveinsight

SEPTEMBER 8, 2021

The exact cause of SLE is unknown; however, factors such as sunlight and drugs may precipitate the condition, and many studies have revealed a complex genetic basis. Baricitinib, also known as LY3009104 or INCB028050 , is a novel orally bioavailable inhibitor of the tyrosine-protein kinase JAK1 or JAK2. Baricitinib (INCB-028050).

Marketing

Marketing Sales FDA Approval Antibody

Clinical Research Informer

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence?

Stay Connected